The post AAVE Price Prediction: Targets $190-195 Range by February 2026 appeared on BitcoinEthereumNews.com. Rebeca Moen Jan 15, 2026 10:20 AAVE price predictionThe post AAVE Price Prediction: Targets $190-195 Range by February 2026 appeared on BitcoinEthereumNews.com. Rebeca Moen Jan 15, 2026 10:20 AAVE price prediction

AAVE Price Prediction: Targets $190-195 Range by February 2026



Rebeca Moen
Jan 15, 2026 10:20

AAVE price prediction shows bullish momentum toward $190-195 by February despite mixed signals. Technical analysis reveals key resistance at $184 with strong support holding.

Aave (AAVE) is currently trading at $176.10, showing resilience above key support levels despite a slight 0.38% decline in the past 24 hours. Recent technical analysis and analyst forecasts suggest potential upside toward the $190-195 range in the coming weeks.

AAVE Price Prediction Summary

Short-term target (1 week): $184-186
Medium-term forecast (1 month): $190-195 range
Bullish breakout level: $184.57
Critical support: $171.90

What Crypto Analysts Are Saying About Aave

Recent analyst sentiment has turned cautiously optimistic for AAVE’s near-term prospects. Caroline Bishop noted on January 10, 2026: “AAVE price prediction shows potential rally to $190-$195 range by February 2026, driven by oversold RSI recovery and analyst targets up to $213. Current $165 level offers entry opportunity.”

Felix Pinkston provided an updated Aave forecast on January 12, stating: “AAVE price prediction shows potential upside to $190 by month-end despite current $164.45 trading level, with technical analysis revealing mixed signals and analyst targets up to $195.”

Joerg Hiller highlighted the technical setup, observing that “Recent analyst forecasts suggest AAVE could rally 18-25% from current levels, with technical indicators showing mixed signals as the token trades at $167.02.”

These predictions align with the current technical picture showing AAVE trading well above the levels where these forecasts were made.

AAVE Technical Analysis Breakdown

The current technical landscape for AAVE presents a mixed but potentially bullish setup. With an RSI of 56.11, the token sits in neutral territory, suggesting neither overbought nor oversold conditions. This provides room for upward movement without immediate momentum exhaustion.

The MACD histogram currently shows 0.0000, indicating bearish momentum has stalled, though a clear bullish crossover has yet to emerge. More encouraging is AAVE’s position within the Bollinger Bands, trading at 0.82 of the band width, placing it near the upper resistance at $183.12 but with room to push higher.

Key moving averages tell an interesting story. AAVE trades above both the 7-day SMA ($170.84) and 20-day SMA ($163.63), confirming short-term bullish momentum. However, it remains below the 200-day SMA at $244.82, indicating the broader trend recovery is still incomplete.

Critical resistance levels include immediate resistance at $180.33 and strong resistance at $184.57. On the downside, immediate support sits at $171.90, with stronger support at $167.71.

Aave Price Targets: Bull vs Bear Case

Bullish Scenario

In the bullish case, AAVE breaks above the $184.57 resistance level, which would confirm the analyst targets of $190-195. This scenario requires:

  • RSI maintaining above 50 while approaching overbought territory
  • MACD generating a clear bullish crossover
  • Trading volume increasing above the current $17.2 million daily average
  • Bitcoin and broader crypto market maintaining stability

A successful breakout could see AAVE testing the upper Bollinger Band at $183.12 initially, then targeting the $190-195 range by February as predicted by multiple analysts.

Bearish Scenario

The bearish case involves AAVE failing to hold current support levels. Key risk factors include:

  • Breaking below $171.90 immediate support
  • RSI dropping below 50 into bearish territory
  • MACD histogram turning significantly negative
  • Broader crypto market weakness

If bearish momentum takes hold, AAVE could retest the strong support at $167.71, with further downside potentially targeting the lower Bollinger Band around $144.13.

Should You Buy AAVE? Entry Strategy

Based on current technical conditions, potential entry strategies include:

Conservative Approach: Wait for a pullback to the $171-173 range, which coincides with the 7-day moving average and immediate support. This provides better risk-reward positioning.

Aggressive Approach: Enter near current levels around $176, with a stop-loss below $171 to limit downside risk.

Breakout Strategy: Wait for a confirmed break above $184.57 with volume, then enter on the retest of this level as new support.

Risk management remains crucial given AAVE’s daily ATR of $9.47, indicating significant volatility. Position sizing should account for potential 5-6% daily moves.

Conclusion

The AAVE price prediction points toward a bullish February, with analyst targets of $190-195 appearing achievable based on current technical setup. The token’s position above key short-term moving averages and neutral RSI provides a foundation for upward movement.

However, mixed momentum indicators suggest caution is warranted. Success depends on breaking the $184.57 resistance level with conviction. Current support at $171.90 must hold to maintain the bullish Aave forecast.

With a moderate confidence level of 65%, the $190-195 target by February represents a reasonable expectation, though traders should prepare for volatility and maintain proper risk management.

Disclaimer: This AAVE price prediction is for educational purposes only and should not be considered financial advice. Cryptocurrency investments carry significant risk, and past performance does not guarantee future results. Always conduct your own research before making investment decisions.

Image source: Shutterstock

Source: https://blockchain.news/news/20260115-aave-price-prediction-targets-190-195-range-by-february-2026

Market Opportunity
AaveToken Logo
AaveToken Price(AAVE)
$170.99
$170.99$170.99
-1.67%
USD
AaveToken (AAVE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23